| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia BJ Druker, F Guilhot, SG O'Brien, I Gathmann, H Kantarjian, N Gattermann, ... New England Journal of Medicine 355 (23), 2408-2417, 2006 | 4388 | 2006 |
| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ... Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013 | 2555 | 2013 |
| The molecular biology of chronic myeloid leukemia MWN Deininger, JM Goldman, JV Melo Blood, The Journal of the American Society of Hematology 96 (10), 3343-3356, 2000 | 2287 | 2000 |
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis S Verstovsek, RA Mesa, J Gotlib, RS Levy, V Gupta, JF DiPersio, ... New England Journal of Medicine 366 (9), 799-807, 2012 | 2208 | 2012 |
| Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet M Baccarani, J Cortes, F Pane, D Niederwieser, G Saglio, J Apperley, ... Journal of clinical oncology 27 (35), 6041, 2009 | 1855 | 2009 |
| Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet M Baccarani, G Saglio, J Goldman, A Hochhaus, B Simonsson, ... Blood 108 (6), 1809-1820, 2006 | 1825 | 2006 |
| The development of imatinib as a therapeutic agent for chronic myeloid leukemia M Deininger, E Buchdunger, BJ Druker Blood 105 (7), 2640-2653, 2005 | 1658 | 2005 |
| Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL … T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ... Blood 108 (1), 28-37, 2006 | 1528 | 2006 |
| Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at … CL Sawyers, A Hochhaus, E Feldman, JM Goldman, CB Miller, ... Blood, The Journal of the American Society of Hematology 99 (10), 3530-3539, 2002 | 1528 | 2002 |
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study M Talpaz, RT Silver, BJ Druker, JM Goldman, C Gambacorti-Passerini, ... Blood, The Journal of the American Society of Hematology 99 (6), 1928-1937, 2002 | 1464 | 2002 |
| AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance T O'Hare, WC Shakespeare, X Zhu, CA Eide, VM Rivera, F Wang, ... Cancer cell 16 (5), 401-412, 2009 | 1409 | 2009 |
| In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants T O'Hare, DK Walters, EP Stoffregen, T Jia, PW Manley, J Mestan, ... Cancer research 65 (11), 4500-4505, 2005 | 1359 | 2005 |
| Long-term outcomes of imatinib treatment for chronic myeloid leukemia A Hochhaus, RA Larson, F Guilhot, JP Radich, S Branford, TP Hughes, ... New England Journal of Medicine 376 (10), 917-927, 2017 | 1244 | 2017 |
| A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ... New England Journal of Medicine 369 (19), 1783-1796, 2013 | 1229 | 2013 |
| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ... Leukemia 34 (4), 966-984, 2020 | 1221 | 2020 |
| Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance FX Mahon, MWN Deininger, B Schultheis, J Chabrol, J Reiffers, ... Blood, The Journal of the American Society of Hematology 96 (3), 1070-1079, 2000 | 1098 | 2000 |
| Functional genomic landscape of acute myeloid leukaemia JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ... Nature 562 (7728), 526-531, 2018 | 1050 | 2018 |
| Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity AS Corbin, A Agarwal, M Loriaux, J Cortes, MW Deininger, BJ Druker The Journal of clinical investigation 121 (1), 396-409, 2011 | 939 | 2011 |
| International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed … M Deininger, SG O'Brien, F Guilhot, JM Goldman, A Hochhaus, ... Blood 114 (22), 1126, 2009 | 928 | 2009 |
| The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL–positive cells MWN Deininger, JM Goldman, N Lydon, JV Melo Blood, The Journal of the American Society of Hematology 90 (9), 3691-3698, 1997 | 911 | 1997 |
